Intellia Therapeutics (NTLA) Research & Development (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Research & Development data on file, last reported at $80.7 million in Q1 2026.

• Research & Development for Q1 2026 came in at $80.7 million, down 25.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $361.2 million (down 21.97% YoY), and the FY2025 annual result was $388.9 million, down 16.61% from the prior year.
• Research & Development fell to $80.7 million in Q1 2026 per NTLA's latest filing, from $88.7 million in the prior quarter.
• Over five years, Research & Development peaked at $133.1 million in Q1 2022 and troughed at $80.7 million in Q1 2026.
• A 5-year average of $105.4 million and a median of $108.4 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 238.87% in 2022, then fell 27.03% in 2023.
• A 5-year view of Research & Development shows it stood at $100.0 million in 2022, then gained by 8.94% to $109.0 million in 2023, then rose by 7.25% to $116.9 million in 2024, then declined by 24.15% to $88.7 million in 2025, then retreated by 8.93% to $80.7 million in 2026.
• Business Quant data shows NTLA's Research & Development at $80.7 million in Q1 2026, $88.7 million in Q4 2025, and $94.7 million in Q3 2025.